Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.36 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains cautiously optimistic about the company's future prospects. They emphasized their commitment to advancing their therapeutic programs.
Management expressed hope for future developments in their pipeline.
They highlighted ongoing efforts to enhance operational efficiency.
Despite reporting a loss per share, Soleno Therapeutics saw a positive stock reaction, rising 4.18%. This increase may reflect investor optimism regarding the company's future plans and ongoing projects. The lack of revenue data and guidance indicates uncertainty, but management's comments suggest they are focused on improving operations and advancing their pipeline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARA HLDGS INC
Aug 13, 2018